LETTER TO THE EDITOR

Open Access



Identification of IGF1R mutation as a novel predictor of efficacious immunotherapy in melanoma

Dongshen Ma¹, Qin Zhang², Qianqian Duan², Yuan Tan², Tingting Sun², Chuang Qi², Yong Qin² and Hui Liu^{1*}

To the editor,

Insulin-like growth factor-1 receptor (IGF-1R), a member of the tyrosine protein kinase receptor family, displays potent anti-apoptotic and pro-survival capacities and plays a key role in malignant transformation [1]. Previous studies revealed IGF1R-mediated resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma [2]. However, other research indicated that IGF1R is closely connected with high degrees of tumor infiltrates and some immune-related gene expression, which showed the potential of IGF1R in pan-cancer immunotherapy [3]. Therefore, exploring the role of IGF1R in melanoma immunotherapy may provide an alternative treatment option for target-resistant melanoma. To the best of our knowledge, no study has reported the efficacy of immunotherapy in melanoma with IGF1R mutation.

First, 418 melanoma samples derived from seven whole exome sequencing (WES) immunotherapy studies were

used to evaluate the association between IGF1R mutation and the efficacy of immunotherapy (http://www.cbiop ortal.org/). The study design and clinical information of these patients are shown in Additional file 1: Figure S1 and Additional file 3: Table S1. The results demonstrated that patients with IGF1R mutations harbored a significantly prolonged overall survival (OS) (mOS: NR vs. 22.7 months, HR: 0.35, 95% CI: 0.15–0.86, P = 0.016, Fig. 1A). This relationship remained stable in the multivariate-adjusted Cox model incorporating confounding factors (HR: 0.35, 95% CI: 0.14–0.84, P = 0.019; Fig. 1B). In addition, IGF1R-mutant melanoma had a good clinical response (overall response rate, ORR: 55.56% vs. 33.33%, P=0.042; Disease control rate, DCR: 77.78% vs. 44.56%, P = 0.007, Fig. 1C and 1D). The predictive value of IGF1R was then validated in 320 melanoma patients from the MSKCC cohort (http://www.cbioportal.org/). Samples with IGF1R mutation had improved OS (mOS:

(See figure on next page.)

Fig. 1 The predictive value of IGF1R mutation in immunotherapy of melanoma. A Kaplan–Meier survival analysis comparing OS between IGF1R mutant and wildtype patients in the combination of five WES cohorts. B Multivariate Cox regression analysis of IGF1R mutations in WES cohorts with age, sex, tumor site and treatment method taken into account. C Comparison of the ORR between the IGF1R mutant and wildtype groups from WES cohorts. D Comparison of the DCR between the IGF1R mutant and wildtype groups from WES cohorts. E Kaplan–Meier survival analysis comparing OS between IGF1R mutant and wildtype patients in the MSKCC cohort. F Multivariate Cox regression analysis of IGF1R mutations in the combination of MSKCC cohort with age, sex, tumor sites and treatment methods were taken into account


Full list of author information is available at the end of the article




© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and you rintended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data

^{*}Correspondence: LiuHui_20220225@163.com

¹ Department of Pathology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China





(See figure on previous page.)

Fig. 2 IGF1R mutation was associated with high TMB, DDR mutation and enhanced tumor immunity. A Comparison of the TMB between the IGF1R mutant and wildtype groups from WES cohorts. B Comparison of the TMB between the IGF1R mutant and wildtype groups from the MSKCC cohort. C Comparison of the TNB between the IGF1R mutant and wildtype groups from the WES cohorts. D Comparison of DNA damage-related gene set variants between IGF1R mutant and wildtype patients. E Bubble plot showing the enrichment of DNA repair- and oxidative phosphorylation-related pathways in IGF1R mutation patients relative to wildtype patients in advanced melanoma of WES cohorts. F DNA repair pathway. G Oxidative phosphorylation pathway

not reach, NR vs. 42.0 months, HR: 0.34, 95% CI: 0.12–0.92, $P\!=\!0.025$, Fig. 1E). After taking into account the same confounding factors, the multivariate-adjusted Cox model showed that patients with IGF1R mutations harbored a markedly preferable immunotherapy prognosis than those without such mutations (HR: 0.35, 95% CI: 0.13–0.95, $P\!=\!0.039$; Fig. 1F). To assess to prognostic value of IGF1R, survival analysis was performed according to IGF1R mutational status in TCGA cohort. No significant difference was found in OS between IGF1R-Mut and IGF1R-Wt subtypes in melanoma (mOS: 268.5 vs. 78.9 months, $P\!=\!0.38$, Additional file 2: Figure S2).

Considering the superior predictive value of IGF1R in melanoma immunotherapy, we further explored the potential mechanisms. The results showed that IGF1Rmutant tumors had a higher tumor mutation burden (TMB) in both the WES cohort and the MSKCC cohort (Fig. 2A and 2B). Patients with IGF1R mutations exhibited significantly higher tumor neoantigen burden (TNB) than those without IGF1R mutations (Fig. 2C). In addition, IGF1R-mutant samples had significantly increased mutations in the DNA damage response (DDR) pathway (Fig. 2D). Gene set enrichment analysis (GSEA) showed significant enrichment of DNA repair- and oxidative phosphorylation-related pathways in advanced melanoma patients with IGF1R mutation compared to the wildtype (Fig. 2E-G). These results suggested that IGF1R mutation increased tumor immunity.

In summary, our research revealed a favorable link between IGF1R mutation and better clinical outcomes of immunotherapy melanoma patients. Therefore, IGF1R mutation could serve as a predictive biomarker for melanoma patients. Furthermore, validation of the predictive value of IGF1R in prospective trials and more fundamental exploration of its molecular mechanism are needed in the future.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03324-8.

Additional file 1: Figure S1. Flowchart of the study design. A Merger of discovery cohorts from seven published studies (Synder et al. [1], Roh et al. [2], Riaz et al. [3], Liu et al. [4], Hugo et al. [5], Miao et al. [6], Allen et al. [7]). B Validation cohort from the published study (Samstein et al. [8]). C TCGA dataset was used to perform prognostic analysis and pathway enrichment analysis.

Additional file 2: Figure S2. Kaplan-Meier curves of OS between IGF1R-Mut and wildtype group in the TCGA cohort.

Additional file 3: Table S1. Detailed clinical information of seven WES cohorts and the MSKCC cohort.

Acknowledgements

None

Authors' contributions

Conception and design: HL, DM; administrative support: QZ, QD, TS, CQ; provision of study materials or patients: HL, DM; collection and assembly of data: QZ, QD, YT; data analysis and interpretation: QZ, QD, YT; manuscript writing: all authors. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

All data generated or analyzed in this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

Since the study is based on public data, the informed consent and ethical proof are not required.

Consent for publication

All authors give their consent to publish this manuscript.

Competing interests

The authors have no relevant financial or non-financial interests to disclose.

Author details

¹Department of Pathology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China. ²The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co. Ltd, Building 5, No. 699-18 Xuanwu Avenue, Xuanwu District, Nanjing, Jiangsu, China.

Received: 27 February 2022 Accepted: 28 February 2022 Published online: 11 April 2022

References

- Werner H, Sarfstein R, Bruchim I. Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy. Expert Opin Investig Drugs. 2019;28:1101–12.
- Patel H, Mishra R, Yacoub N, Alanazi S, Kilroy MK, Garrett JT. IGF1R/IR mediates resistance to BRAF and MEK inhibitors in BRAF-mutant melanoma. Cancers (Basel). 2021;13:5863.
- Zhang Y, Gao C, Cao F, et al. Pan-cancer analysis of IGF-1 and IGF-1R as potential prognostic biomarkers and immunotherapy targets. Front Oncol. 2021;11:755341.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

